ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma
ZIOPHARM Oncology, Inc. today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.